Pityriasis lichenoides et varioliformis acuta following anti-tetanus and diphtheria adult vaccine

Merlotto, Maira Renata; Bicudo, Natália Parenti; Marques, Mariângela Esther Alencar; Marques, Sílvio Alencar

doi:10.1016/j.abd.2019.06.009

Cited by 8 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This theory is supported by frequent reports of preceding or concurrent infection or vaccination (measles/mumps/rubella, antitetanus and antidiphtheria, and influenza). [2][3][4][5] Due to its resemblance to lymphomatoid papulosis and common clonality, PLEVA has also been theorized to be a primary lymphoproliferative disorder. 5 In case 1, we hypothesize that a robust immune response to the messenger RNA component of the COVID-19 vaccine may have triggered the patient's presentation.…”

Section: Discussionmentioning

confidence: 99%

Rare lymphomatoid reactions following SARS-CoV-2 vaccination

LeWitt

Chung

Manton³

et al. 2022

JAAD Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Rare lymphomatoid reactions following SARS-CoV-2 vaccination

LeWitt

Chung

Manton³

et al. 2022

JAAD Case Reports

View full text Add to dashboard Cite

“…It is known to be triggered by extrinsic antigens such as infectious agents, drugs and vaccines. 2 Only 10 reports of vaccine‐induced cases were previously documented following different types of vaccines such as measles, rubella, mumps, influenza, adult tetanus, diphtheria, and human papilloma virus vaccines. 3 …”

Section: Figurementioning

confidence: 99%

“…It is either an inflammatory skin reaction secondary to the vaccine as a trigger or vaccine‐induced activation of immune‐complex mediated hypersensitivity reaction and/or T‐cell clonal proliferation. 2 These events could be sequalae to the up‐regulated inflammatory/immunological reactions or cross reactivity between viral particles or adjuvant molecules and self‐antigens. 4 However, in our patient, the absence of recurrent lesions following COVID‐19 infection signifies that the reaction was vaccine related and not virus correlated.…”

Section: Figurementioning

confidence: 99%

“…The data that support the findings of this study are available from the corresponding author upon reasonable request. Noha Mohammed Dawoud 1,2 Huma Aslam 3,4 Ishraga Mahmoud Ali 2 Marwa Mohammed Dawoud 5…”

Section: Data Availability Statementmentioning

confidence: 99%

“…It is known to be triggered by extrinsic antigens such as infectious agents, drugs and vaccines. 2 Only 10 reports of vaccine-induced cases were previously documented following different types of vaccines such as measles, rubella, mumps, influenza, adult tetanus, diphtheria, and human papilloma virus vaccines. 3 Up to date, pityriasis lichenoides et varioliformis acuta (PLEVA) and PLEVA-like eruption has been reported three times following BioNTech/Pfizer COVID-19 vaccination (Table 1).…”

mentioning

confidence: 99%

See 2 more Smart Citations

The first case report of Pityriasis lichenoides chronica following COVID ‐19 mRNA vaccination

Dawoud

Aslam

Ali

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Many cutaneous adverse reactions to the Coronavirus disease-2019 (COVID-19) vaccines have been reported. Delayed reactions, which occur following several days or weeks, either involve new onset cutaneous disorder or flare of preexisting dermatomes. Here, we report the first case of new onset Pityriasis lichenoides chronica (PLC) following the Pfizer-BioNTech COVID-19 mRNA vaccine, aiming to highlight their possible association.An adolescent 16-year-old boy experienced gradual onset of asymptomatic scaly erythematous papules over his trunk (Figure 1A, B). The eruption started 1 week after the first dose of the Pfizer-BioNTech COVID-19 vaccine. However, the patient did not seek medical advice or receive any treatment. Following the second dose, the eruption increased progressively all over the trunk and extremities, with the appearance of numerous purpuric lesions. Mucous mem-

show abstract

Pityriasis Lichenoides Following SARS-CoV-2 Infection/Vaccination

et al. 2023

View full text Add to dashboard Cite

Purpose of Review Pityriasis lichenoides (PL) is a spectrum of dermatological conditions involving polymorphous lesions. Natural history of the condition ranges from acute to chronic. Cases of PL following SARS-CoV-2 infection/vaccination have been reported, but not yet comprehensively reviewed. Hence, the objective of this article is to review and summarize cases of PL following SARS-CoV-2 infection/vaccination in order to guide clinicians in its diagnosis and management. Recent Findings PubMed, Embase, and Web of Science were searched for relevant articles. Thirteen articles, consisting of 14 cases of PL following SARS-CoV-2 infection/vaccination, were identified. Males represented 64.3% of cases, and the average age of those affected was 41.4 years. The majority of cases ( N = 9, 64.3%) were following SARS-CoV-2 vaccination, the most commonly implicated being Pfizer-BioNTech ( n = 8/10, 80%), while four (28.6) followed infection. The overall latency period ranged from 5 days to 1 month. Treatments varied greatly. However, at the time of follow-up, 12/14 patients (85.7%) had either marked improvement or complete resolution of lesions. Summary This review cannot determine causality. However, a temporal association was observed with the case reports, and one case of PL followed SARS-CoV-2 infection and recurred with subsequent vaccination, suggesting an association. Nevertheless, risk of developing PL following SARS-CoV-2 infection/vaccination is likely extremely low. There is also the possibility these cases are purely coincidental. Still, clinicians should be aware of this possible etiology when diagnosing a new or exacerbated case of PL. Finally, given that the majority of patients had marked improvement or complete resolution of lesions at the time of follow-up, clinicians should provide reassurance to their affected patients.

show abstract

Pityriasis lichenoides et varioliformis acuta following anti-tetanus and diphtheria adult vaccine

Cited by 8 publications

References 5 publications

Rare lymphomatoid reactions following SARS-CoV-2 vaccination

Rare lymphomatoid reactions following SARS-CoV-2 vaccination

The first case report of Pityriasis lichenoides chronica following COVID ‐19 mRNA vaccination

Pityriasis Lichenoides Following SARS-CoV-2 Infection/Vaccination

Contact Info

Product

Resources

About